Metformin Alters mRNA Expression of FOXP3, RORC, and TBX21 and Modulates Gut Microbiota in COVID-19 Patients with Type 2 Diabetes
Pavlo Petakh, Iryna Kamyshna, Valentyn Oksenych, Oleksandr Kamyshnyi
Viruses, doi:10.3390/v16020281
COVID-19 remains a significant global concern, particularly for individuals with type 2 diabetes who face an elevated risk of hospitalization and mortality. Metformin, a primary treatment for type 2 diabetes, demonstrates promising pleiotropic properties that may substantially mitigate disease severity and expedite recovery. Our study of the gut microbiota and the mRNA expression of pro-inflammatory and anti-inflammatory T-lymphocyte subpopulations showed that metformin increases bacterial diversity while modulating gene expression related to T-lymphocytes. This study found that people who did not take metformin had a downregulated expression of FOXP3 by 6.62fold, upregulated expression of RORC by 29.0-fold, and upregulated TBX21 by 1.78-fold, compared to the control group. On the other hand, metformin patients showed a 1.96-fold upregulation in FOXP3 expression compared to the control group, along with a 1.84-fold downregulation in RORC expression and an 11.4-fold downregulation in TBX21 expression. Additionally, we found a correlation with gut microbiota (F/B ratio and alpha-diversity index) and pro-inflammatory biomarkers. This novel observation of metformin's impact on T-cells and gut microbiota opens new horizons for further exploration through clinical trials to validate and confirm our data. The potential of metformin to modulate immune responses and enhance gut microbiota diversity suggests a promising avenue for therapeutic interventions in individuals with type 2 diabetes facing an increased risk of severe outcomes from COVID-19.
Author Contributions: Conceptualization, O.K.; methodology, O.K.; software, O.K.; validation, O.K. and P.P.; formal analysis, P.P.; investigation, O.K.; data curation, O.K.; writing-original draft preparation, P.P.; writing-review and editing, V.O.; visualization, P.P.; supervision, O.K.; project administration, I.K. All authors have read and agreed to the published version of the manuscript. Funding: This research received no external funding.
Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of I. Horbachevsky Ternopil National Medical University (protocol code 74 on 1 September 2023). Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.
Conflicts of Interest: The authors declare no conflicts of interest.
References
Blagih, Coulombe, Vincent, Dupuy, Galicia-Vázquez et al., The Energy Sensor AMPK Regulates T Cell Metabolic Adaptation and Effector Responses In Vivo, Immunity,
doi:10.1016/j.immuni.2014.12.030Cao, Baranova, Wei, Wang, Zhang, Bidirectional causal associations between type 2 diabetes and COVID-19, J. Med. Virol,
doi:10.1002/jmv.28100Capone, Volpe, Transcriptional Regulators of T Helper 17 Cell Differentiation in Health and Autoimmune Diseases, Front. Immunol,
doi:10.3389/fimmu.2020.00348Chen, Zhou, Wang, Huang, Advances in metformin-based metabolic therapy for non-small cell lung cancer (Review), Oncol. Rep,
doi:10.3892/or.2022.8266Chi, Regulation and function of mTOR signalling in T cell fate decisions, Nat. Rev. Immunol,
doi:10.1038/nri3198De Gregoris, Aldred, Clare, Burgess, Improvement of phylum-and class-specific primers for real-time PCR quantification of bacterial taxa, J. Microbiol. Methods,
doi:10.1016/j.mimet.2011.06.010Hiscott, Alexandridi, Muscolini, Tassone, Palermo et al., The global impact of the coronavirus pandemic, Cytokine Growth Factor Rev,
doi:10.1016/j.cytogfr.2020.05.010Kamyshnyi, Matskevych, Lenchuk, Strilbytska, Storey et al., Metformin to decrease COVID-19 severity and mortality: Molecular mechanisms and therapeutic potential, Biomed. Pharmacother,
doi:10.1016/j.biopha.2021.112230Kondȇlková, Vokurková, Krejsek, Borská, Fiala et al., Regulatory T cells (TREG) and their roles in immune system with respect to immunopathological disorders, Acta Medica,
doi:10.14712/18059694.2016.63Livak, Schmittgen, Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2 -∆∆CT Method, Methods,
doi:10.1006/meth.2001.1262Oestreich, Weinmann, Transcriptional mechanisms that regulate T helper 1 cell differentiation, Curr. Opin. Immunol,
doi:10.1016/j.coi.2011.12.004Petakh, Griga, Mohammed, Loshak, Poliak et al., Effects of Metformin, Insulin on Hematological Parameters of COVID-19 Patients with Type 2 Diabetes, Med. Arch,
doi:10.5455/medarh.2022.76.329-332Petakh, Isevych, Mohammed, Loshak, Poliak et al., Association between Use of Metformin and Insulin with Hematological Parameters in COVID-19 Patients with Type 2 Diabetes: A Single Center, Cross-Sectional Study, Clin. Diabetol,
doi:10.5603/DK.a2022.0055Petakh, Kamyshna, Kamyshnyi, Gene expression of protein kinase AMP-activated catalytic subunit alpha 1 (PRKAA1), solute carrier family 2 member 1 (SLC2A1) and mechanistic target of rapamycin (MTOR) in metformin-treated type 2 diabetes patients with COVID-19: Impact on inflammation markers, Inflammopharmacology,
doi:10.1007/s10787-023-01341-7Petakh, Kamyshna, Kamyshnyi, Unveiling the potential pleiotropic effects of metformin in treating COVID-19: A comprehensive review, Front. Mol. Biosci,
doi:10.3389/fmolb.2023.1260633Petakh, Kamyshna, Nykyforuk, Yao, Imbery et al., Immunoregulatory Intestinal Microbiota and COVID-19 in Patients with Type Two Diabetes: A Double-Edged Sword, J. Viruses,
doi:10.3390/v14030477Petakh, Kamyshna, Oksenych, Kainov, Kamyshnyi, Metformin Therapy Changes Gut Microbiota Alpha-Diversity in COVID-19 Patients with Type 2 Diabetes: The Role of SARS-CoV-2 Variants and Antibiotic Treatment, Pharmaceuticals,
doi:10.3390/ph16060904Petakh, Kobyliak, Kamyshnyi, Gut microbiota in patients with COVID-19 and type 2 diabetes: A culture-based method, Front. Cell. Infect. Microbiol,
doi:10.3389/fcimb.2023.1142578Petakh, Loshak, Kamyshnyi, Hematological features of patients with type 2 diabetes depending on the variant of SARS-CoV-2, Fiziolohichnyȋ Zhurnal,
doi:10.15407/fz69.01.035Petakh, Oksenych, Kamyshnyi, The F/B ratio as a biomarker for inflammation in COVID-19 and T2D: Impact of metformin, Biomed. Pharmacother,
doi:10.1016/j.biopha.2023.114892Polidori, Marullo, Ialongo, Tomassetti, Colombo et al., Characterization of Gut Microbiota Composition in Type 2 Diabetes Patients: A Population-Based Study, Int. J. Environ. Res. Public Health,
doi:10.3390/ijerph192315913Reis, Silva, Silva, Thabane, Milagres et al., Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with COVID-19: The TOGETHER randomized platform clinical trial, Lancet Reg. Health Am
Salminen, Hyttinen, Kaarniranta, AMP-activated protein kinase inhibits NF-κB signaling and inflammation: Impact on healthspan and lifespan, J. Mol. Med,
doi:10.1007/s00109-011-0748-0Sharma, Behl, Sharma, Singh, Grewal et al., COVID-19 and diabetes: Association intensify risk factors for morbidity and mortality, Biomed. Pharmacother,
doi:10.1016/j.biopha.2022.113089Tulipano, Integrated or Independent Actions of Metformin in Target Tissues Underlying Its Current Use and New Possible Applications in the Endocrine and Metabolic Disorder Area, Int. J. Mol. Sci,
doi:10.3390/ijms222313068Ventura-López, Cervantes-Luevano, Aguirre-Sánchez, Flores-Caballero, Alvarez-Delgado et al., Treatment with metformin glycinate reduces SARS-CoV-2 viral load: An in vitro model and randomized, double-blind, Phase IIb clinical trial, Biomed. Pharmacother,
doi:10.1016/j.biopha.2022.113223Yu, Li, Sun, Wang, Insulin treatment is associated with increased mortality in patients with COVID-19 and type 2 diabetes, J. Cell Metab,
doi:10.1016/j.cmet.2020.11.014Zhao, Liu, Yi, Zhang, Xu et al., Type 2 diabetes mellitus impaired nasal immunity and increased the risk of hyposmia in COVID-19 mild pneumonia patients, Int. Immunopharmacol,
doi:10.1016/j.intimp.2021.107406Zhou, Myers, Li, Chen, Shen et al., Role of AMP-activated protein kinase in mechanism of metformin action, J. Clin. Investig,
doi:10.1172/JCI13505
